David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared a post on LinkedIn about a paper he co-authored with colleagues published in NEJM.
“After ADCs, HER2-TKIs arrive…impressive clinical activity and tolerance! Things are moving fast, but access is still difficult in Europe outside a clinical trial…unfortunately for our HER2-mutant patients!”
Title: Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
Authors: John Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert Smit, David Planchard, Yi-Long Wu, Byoung Chul Cho, Noboru Yamamoto, Joshua Sabari, Yanqiu Zhao, Hai-Yan Tu, Kiyotaka Yoh, Ernest Nadal, Behbood Sadrolhefazi, Maren Rohrbacher, Ute von Wangenheim, Sabina Eigenbrod-Giese, Jon Zugazagoitia.
You can read the Full Article on NEJM.
More posts featuring David Planchard.
